Skip to content

CHINA PHARMA HOLDINGS, INC.: 10-Q filed 2026-08-14

What CHINA PHARMA HOLDINGS, INC. reported in its quarterly report filed 2026-08-14 (fiscal Q2 2026): 50 published measures, 146 facts as tagged in accession 0001213900-26-090173.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-14
Fiscal period
fiscal Q2 2026
Accession
0001213900-26-090173 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CHINA PHARMA HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-3044,709,903USD
At 2025-12-3130,999,464USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-308,528,623USD
At 2025-12-318,259,712USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-3036,181,280USD
At 2026-03-3137,024,190USD
At 2025-12-3122,739,752USD
At 2025-06-306,461,744USD
At 2025-03-316,969,848USD
At 2024-12-317,747,904USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-30304,874USD
At 2025-12-31345,112USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,458,123USD91
2026-01-01 to 2026-06-30-2,601,271USD181
2026-01-01 to 2026-03-31-1,143,148USD90
2025-04-01 to 2025-06-30-528,367USD91
2025-01-01 to 2025-06-30-1,313,939USD181
2025-01-01 to 2025-03-31-785,572USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-88,120USD181
2025-01-01 to 2025-06-30200,631USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-01-01 to 2025-06-3058,259USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-04-01 to 2026-06-30948,340USD91
2026-01-01 to 2026-06-301,931,876USD181
2025-04-01 to 2025-06-301,025,767USD91
2025-01-01 to 2025-06-302,162,054USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-3040,793USD181
2025-01-01 to 2025-06-30-99,221USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-58,259USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-49,815,506USD
At 2025-12-31-47,214,235USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-3040,522,002shares91
2026-01-01 to 2026-06-3034,087,748shares181
2025-04-01 to 2025-06-303,226,156shares91
2025-01-01 to 2025-06-303,261,956shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-3040,522,002shares91
2026-01-01 to 2026-06-3034,087,748shares181
2025-04-01 to 2025-06-303,226,156shares91
2025-01-01 to 2025-06-303,261,956shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.04USD/shares91
2026-01-01 to 2026-06-30-0.08USD/shares181
2025-04-01 to 2025-06-30-0.16USD/shares91
2025-01-01 to 2025-06-30-0.4USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.04USD/shares91
2026-01-01 to 2026-06-30-0.08USD/shares181
2025-04-01 to 2025-06-30-0.16USD/shares91
2025-01-01 to 2025-06-30-0.4USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-06-304,219,763USD
At 2025-12-314,391,964USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD91
2026-01-01 to 2026-06-300USD181
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-300USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,431,845USD91
2026-01-01 to 2026-06-30-2,549,109USD181
2025-04-01 to 2025-06-30-652,120USD91
2025-01-01 to 2025-06-30-1,410,738USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-302,006,618USD
At 2025-12-312,346,407USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2026-04-01 to 2026-06-309,306USD91
2026-01-01 to 2026-06-3018,391USD181
2025-04-01 to 2025-06-306,771USD91
2025-01-01 to 2025-06-3013,558USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-307,681,602USD
At 2025-12-317,400,359USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2026-06-3037,984,334USD
At 2025-12-3123,743,419USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2026-06-30181,621USD
At 2025-12-31241,412USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,515,411USD91
2026-01-01 to 2026-06-302,918,162USD181
2025-04-01 to 2025-06-30565,110USD91
2025-01-01 to 2025-06-301,187,667USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2026-06-301,362,423USD
At 2025-12-311,621,423USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-3083,566USD91
2026-01-01 to 2026-06-30369,053USD181
2025-04-01 to 2025-06-30-87,010USD91
2025-01-01 to 2025-06-30-223,071USD181

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2026-04-01 to 2026-06-30864,774USD91
2026-01-01 to 2026-06-301,562,823USD181
2025-04-01 to 2025-06-301,112,777USD91
2025-01-01 to 2025-06-302,385,125USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-3019,135USD91
2026-01-01 to 2026-06-30102,897USD181
2025-04-01 to 2025-06-3020,952USD91
2025-01-01 to 2025-06-3050,539USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-3040,522,002shares
At 2025-12-315,522,002shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-06-30304,874USD
At 2025-12-31345,112USD
At 2025-06-30625,032USD
At 2024-12-31626,879USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-3073,504,819USD
At 2025-12-3158,535,819USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-3012,631,445USD
At 2025-12-3111,582,646USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-06-30146,181USD
At 2025-12-31181,828USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2026-06-30148,360USD
At 2025-12-31183,176USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2026-06-3039,077,224USD
At 2025-12-3137,881,815USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2026-06-3034,857,461USD
At 2025-12-3133,489,851USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2026-06-3038,337,341USD
At 2025-12-3124,079,265USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-06-30500,160USD
At 2025-12-31350,643USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2026-06-30153,642USD
At 2025-12-31111,580USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2026-06-3022,500,000USD
At 2025-12-3121,200,000USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2026-06-30771,730USD
At 2025-12-31747,805USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,458,123USD91
2026-01-01 to 2026-06-30-2,601,271USD181
2025-04-01 to 2025-06-30-528,367USD91
2025-01-01 to 2025-06-30-1,313,939USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-842,910USD91
2026-01-01 to 2026-06-30-1,552,472USD181
2025-04-01 to 2025-06-30-508,104USD91
2025-01-01 to 2025-06-30-1,286,161USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,376,974USD91
2026-01-01 to 2026-06-302,603,246USD181
2025-04-01 to 2025-06-30440,834USD91
2025-01-01 to 2025-06-30948,016USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2026-04-01 to 2026-06-30150,327USD91
2026-01-01 to 2026-06-30305,615USD181
2025-04-01 to 2025-06-30163,503USD91
2025-01-01 to 2025-06-30335,104USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2026-04-01 to 2026-06-30951,528USD91
2026-01-01 to 2026-06-301,776,810USD181
2025-04-01 to 2025-06-30157,360USD91
2025-01-01 to 2025-06-30315,072USD181

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-04-01 to 2026-06-3026,359USD91
2026-01-01 to 2026-06-3052,390USD181
2025-04-01 to 2025-06-3027,359USD91
2025-01-01 to 2025-06-3055,387USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-26,278USD91
2026-01-01 to 2026-06-30-52,162USD181
2025-04-01 to 2025-06-30123,753USD91
2025-01-01 to 2025-06-3096,799USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2026-01-01 to 2026-06-3031,605USD181
2025-01-01 to 2025-06-3041,829USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-520,421USD181
2025-01-01 to 2025-06-30-321,431USD181

Inspect the source

Entity
CHINA PHARMA HOLDINGS, INC. / CIK 0001106644
Captured
2026-09-20T05:23:28.377Z
SEC response SHA-256
ad45dffd15d0f5a098ab8b6912816a8b1b845b1d791781ea412833d3178873c0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001106644.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))